BJH - volume 10, issue Abstract Book BHS, february 2019
F. Gelders , A. Laenen , A.A. Herelixka , B. Sprangers MD, PhD, D. Dierickx MD, PhD
BJH - 2018, issue Abstract Book BHS, february 2018
A. Betsch , O. Rutgeerts , S. Fevery MD, PhD, B. Sprangers MD, PhD, D. Dierickx MD, PhD, M. Beckers MD, PhD
BJH - volume 8, issue Abstract Book BHS, february 2017
B. Heymans , B. Sprangers MD, PhD, D. Dierickx MD, PhD
BJH - volume 8, issue Abstract Book BHS, february 2017
B. Heymans , D. Dierickx MD, PhD, B. Sprangers MD, PhD
BJH - volume 7, issue 6, december 2016
M. Beckers MD, PhD, D. Dierickx MD, PhD, T. Devos MD, PhD, S. Fevery MD, PhD, B. Sprangers MD, PhD
One of the hallmarks of failure of elimination of malignant cells by activated T-cells is the immunosuppressive environment of the tumour. Myeloid-derived suppressor cells contribute to this immunosuppressive environment by inhibition of the adaptive and innate immune system. In this article we describe the current knowledge of the role of myeloid-derived suppressor cells in the progression of haematological malignancies.
(BELG J HEMATOL 2016;7(6):213–6)
Read more
Top
To provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site and show (non-) personalized ads. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.
